At the @-mg dose of FX@ , prespecified secondary analyses , including responder analyses and all Western Ontario and McMaster Universities subscales , were significantly superior ( p < @ ) to immediate-release triamcinolone acetonide at eight weeks , and the time-weighted mean pain relief ( assessed with mean daily pain intensity scores ) was significantly superior to immediate-release triamcinolone acetonide over one to twelve weeks ( p = @ ) .